Fig. 4: Longitudinal scRNA-seq analyses for the identification of cellular and molecular reprogramming induced by chemotherapy in AML patients. | Leukemia

Fig. 4: Longitudinal scRNA-seq analyses for the identification of cellular and molecular reprogramming induced by chemotherapy in AML patients.

From: Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia

Fig. 4

A Left: t-SNE visualization of scRNA-seq data of primary refractory patient Pt#3 before and after chemotherapy. Right: Sankey plot showing the dynamic changes of cellular states after chemotherapy in Pt#3. B Left: t-SNE visualization of scRNA-seq data of primary refractory patient Pt#9 before and after chemotherapy. Right: Sankey plot showing the dynamic changes of cellular states after chemotherapy in Pt#9. C Left: t-SNE visualization of scRNA-seq data of Pt#10 who achieved partial remission. Right: Sankey plot showing the dynamic changes of cellular states after chemotherapy in Pt#10. D Sankey plot showing the dynamic changes of cellular states during chemotherapy in samples from the study of Galen et al. E Heatmap for differentially expressed genes after chemotherapy in Pt#3. F Principal component analysis (PCA) of the cellular states in Pt#3 based on the differentially expressed genes during chemotherapy. The dot shape represents the cellular states before or after chemotherapy. G, H Ridge plots showing the activity scores of transcriptional factors GATA2 and TAL1 in QSCs and PSPs during chemotherapy in Pt#3. I The enrichment of GATA2 and TAL1 peaks on gene CD52 based on the ChIP‐Seq data of K562 cell line.

Back to article page